.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Cipla
Mallinckrodt
Cerilliant
Chubb
McKinsey
Boehringer Ingelheim
Harvard Business School
Fuji
US Army

Generated: September 26, 2017

DrugPatentWatch Database Preview

Pf Prism Cv Company Profile

« Back to Dashboard

What is the competitive landscape for PF PRISM CV, and when can generic versions of PF PRISM CV drugs launch?

PF PRISM CV has fourteen approved drugs.

There are forty US patents protecting PF PRISM CV drugs and there have been two Paragraph IV challenges on PF PRISM CV drugs in the past three years.

There are eight hundred and twenty-seven patent family members on PF PRISM CV drugs in seventy-six countries.

Summary for Applicant: Pf Prism Cv

Patents:40
Tradenames:10
Ingredients:10
NDAs:14
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-002Aug 22, 2002ABRXYesYes► Subscribe► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
TABLET;ORAL021266-002May 24, 2002ABRXYesYes► Subscribe► Subscribe► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-002Sep 4, 2012RXYesNo► Subscribe► Subscribe ► Subscribe
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-007Dec 30, 2004RXYesNo► Subscribe► Subscribe ► Subscribe
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-006Dec 30, 2004RXYesNo► Subscribe► SubscribeY ► Subscribe
Pf Prism Cv
VFEND
voriconazole
INJECTABLE;IV (INFUSION)021267-001May 24, 2002APRXYesYes► Subscribe► SubscribeY ► Subscribe
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-001Dec 30, 2004RXYesNo► Subscribe► SubscribeYY ► Subscribe
Pf Prism Cv
XALKORI
crizotinib
CAPSULE;ORAL202570-001Aug 26, 2011RXYesNo► Subscribe► Subscribe ► Subscribe
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-002Dec 30, 2004RXYesNo► Subscribe► SubscribeY ► Subscribe
Pf Prism Cv
LYRICA
pregabalin
SOLUTION;ORAL022488-001Jan 4, 2010RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Pf Prism Cv

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv
VFEND
voriconazole
INJECTABLE;IV (INFUSION)021267-001May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-001Dec 30, 2004► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
INJECTABLE;IV (INFUSION)021267-001May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
INJECTABLE;IV (INFUSION)021267-001May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
INJECTABLE;IV (INFUSION)021267-001May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
LYRICA
pregabalin
SOLUTION;ORAL022488-001Jan 4, 2010► Subscribe► Subscribe
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-007Dec 30, 2004► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
TABLET;ORAL021266-001May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
TABLET;ORAL021266-002May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
TABLET;ORAL021266-002May 24, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PF PRISM CV drugs

Drugname Dosage Strength Tradename Submissiondate
tofacitinib
Tablets5 mg
XELJANZ 
11/7/2016
bosutinib
Tablets100mg and 500mg
BOSULIF
9/6/2016
temsirolimus
Injection25 mg/mL, 1.8 mL vial
TORISEL
5/25/2011
voriconazole
Oral Suspension40 mg/mL
VFEND
10/8/2010
sirolimus
Tablets0.5 mg
RAPAMUNE
8/25/2010
pregabalin
Oral Solution20 mg/mL
LYRICA
5/19/2010
sirolimus
Tablets1 mg and 2 mg
RAPAMUNE
12/17/2009
tigecycline
For Injection50 mg per vial
TYGACIL
6/15/2009
pregabalin
Capsules25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg
LYRICA
12/30/2008
voriconazole
For Injection200 mg/vial
VFEND
9/12/2008
voriconazole
Tablets50 mg and 200 mg
VFEND
4/14/2008

Non-Orange Book Patents for Pf Prism Cv

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,297,258 Substituted 3-cyanoquinolines► Subscribe
7,141,587Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use► Subscribe
6,342,529 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
7,108,865Controlled-release dosage forms of azithromycin► Subscribe
7,842,699Pyrrolo[2,3-D]pyrimidine compounds► Subscribe
6,028,214 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
6,117,906 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
5,847,151 Gaba and L-glutamic acid analogs for antiseizure treatment► Subscribe
8,106,197Aminoheteroaryl compounds as protein kinase inhibitors► Subscribe
7,803,805Cristalline 3-{(3R,4R)-4 methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}- -3-oxo-propionitrile mono citrate salt► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Pf Prism Cv Drugs

Country Document Number Estimated Expiration
China1195755► Subscribe
CroatiaP20020509► Subscribe
Poland179910► Subscribe
Australia777911► Subscribe
Iceland1540► Subscribe
Germany69722426► Subscribe
MexicoPA02005675► Subscribe
Hong Kong1193405► Subscribe
Poland355907► Subscribe
Australia4379493► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Pf Prism Cv Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C017/2008Ireland► SubscribeSPC017/2008: 20090911, EXPIRES: 20200413
155Luxembourg► SubscribePRODUCT NAME: CRIZOTINIB, EVENTUELLEMENT SOUS LA FORME D UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE
C0015France► SubscribePRODUCT NAME: CRIZOTINIB ET SES SELS, HYDRATES ET SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/793/001 20121023
C0037France► SubscribePRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001-005 20010313; FIRST REGISTRATION: IKS55243 20000926
7 5008-2013Slovakia► SubscribePRODUCT NAME: KRIZOTINIB; REGISTRATION NO/DATE: EU/1/12/793/001 - EU/1/12/793/004 20121023
00164Netherlands► SubscribePRODUCT NAME: PREGABALINE, DESGEWENST IN DE; REGISTRATION NO/DATE: EU/1/04/279/001 20040706
00587Netherlands► SubscribePRODUCT NAME: CRIZOTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/12/793/001-004 20121023
0164Netherlands► Subscribe300164, 20130518, EXPIRES: 20180517
1218348/01Switzerland► SubscribePRODUCT NAME: AXITINIB; NAT. REGISTRATION NO/DATE: SWISSMEDIC 62281 20120410
2003005Lithuania► SubscribePRODUCT NAME: VORICONAZOLIS; REGISTRATION NO/DATE: 02/7890/8 20021002
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Baxter
Citi
Fish and Richardson
Dow
Federal Trade Commission
Daiichi Sankyo
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot